Ticker: YARROW-BIOSCIENCES

Yarrow Biosciences

Price —
Potential 0 Risk 0

Track in portfolio

Price chart

AI recommendation Analyst forecast Calendar event Positive signal Negative signal Neutral / update Hold / informational B My buy S My sell
Description

Nothing yet

Nothing yet

News Page 1 of 1
P Y Viking Holdings Yeti Holdings Nucor Humana Ingersoll Rand Tesla Eli Lilly

Analysts UBS upgrade Eli Lilly (LLY) target price to $1,550 and reiterate buy rating

Several analysts have made significant upgrades and downgrades to various stocks, reflecting changing market conditions and company performances. Notably, Eli Lilly's price target was raised, while Yeti was downgraded, indicating a shift in investor sentiment towards these companies.